- Target disease: Leishmaniasis
- Partners (since project start): Laboratory of Microbiology Parasitology and Hygiene, University of Antwerp, Belgium; London School of Hygiene and Tropical Medicine, UK; Pfizer Ltd. (formerly Anacor Pharmaceuticals), UK; Sandexis, UK; Scynexis, USA; Wuxi AppTech, China.
- Project start: 2009
- Funding (since project start): Bill & Melinda Gates Foundation, USA; Department for International Development (DFID), UK; Dutch Ministry of Foreign Affairs (DGIS), the Netherlands; Federal Ministry of Education and Research (BMBF through KfW), Germany; German Corporation for International Cooperation (GIZ) on behalf of the Government of the Federal Republic of Germany, Germany; Global Health Innovative Technology (GHIT) Fund, Japan; Médecins Sans Frontières/Doctors without Borders, International; Ministry of Foreign and European Affairs (MAEE), France; Ministry of Health, Brazil; Spanish Agency for International Development Cooperation (AECID), Spain; Swiss Agency for Development and Cooperation (SDC), Switzerland; Other private foundations and individuals.
DNDi and Anacor have been working together over the last few years to identify oxaborole compounds, initially for the HAT programme, and this has expanded to include both leishmaniasis and Chagas disease. DNDI-6148 has emerged as a promising lead candidate for VL and CL, and by the end of 2015 studies including exploratory toxicology necessary for possible progression to preclinical development had been successfully completed.
Five potential oxaborole back-up compounds have been identified, should DNDI-6148 not succeed in development. Two of these, DNDI-5421 and DNDI-5610, are the most advanced and are being kept ready in case insurmountable issues are identified for DNDI-6148. These compounds have highly efficacious profiles, and if DNDI-6148 should fail we will assess their suitability as viable back-ups.
Further development of these two compounds is currently on hold and will only recommence should problems be encountered with the pre-clinical development of DNDI-6148.
Last update: August 2018